obstructive vascular disease that affects the aorta, carotid, coronary and pulmonary arteries. Previous molecular genetic data have led to the hypothesis that SVAS results from mutations in the elastin gene, ELN. In these studies, the disease phenotype was linked to gross DNA rearrangements (35 and 85 kb deletions and a translocation) in three SVAS families. However, gross rearrangements of ELN have not been identified in most cases of autosomal dominant SVAS. To define the spectrum of ELN mutations responsible for this disorder, we refined the genomic structure of human ELN and used this information in mutational analyses. ELN point mutations co-segregate with the disease in four familial cases and are associated with SVAS in three sporadic cases. Two of the mutations are nonsense, one is a single base pair deletion and four are splice site mutations. In one sporadic case, the mutation arose de novo. These data demonstrate that point mutations of ELN cause autosomal dominant SVAS.
INTRODUCTION
With the exception of hypercholesterolemia and hypertension, little is known about the genetic factors that contribute to vascular disease. Supravalvular aortic stenosis (SVAS) is an inherited obstructive vascular disorder that causes hemodynamically significant narrowing of large arteries (1) . Although the aorta is most frequently diseased, any artery can be affected, including the pulmonary, carotid and coronary arteries. The onset and severity of vascular disease in SVAS is variable. If untreated, this disorder can lead to heart failure, myocardial infarction and death. Currently, the only treatment option is surgery.
SVAS can be inherited as an autosomal dominant trait (1-3) or as one feature of Williams syndrome (Williams syndrome) (2) (3) (4) . In addition to vascular disease, Williams syndrome manifestations include mental retardation, characteristic personality, specific cognitive profile, infantile hypercalcemia, dysmorphic facial features and other connective tissue abnormalities. The incidence of familial and syndromic SVAS is estimated at 1 in 20 000 live births (5) .
Four lines of evidence support a role for ELN in SVAS. First, ELN is genetically linked to the disease phenotype in autosomal dominant SVAS (5) (6) (7) . Second, large DNA rearrangements that disrupt ELN are associated with the disease in three SVAS families (8) (9) (10) . Third, hemizygosity of ELN is observed in individuals with Williams syndrome (11) . Fourth, the structural and functional importance of elastin in large elastic arteries is consistent with a role for ELN in this disease. However, all molecular genetic data implicating ELN in SVAS involve large DNA rearrangements (>550 kb deletions in Williams syndrome; 35 and 85 kb deletions and a translocation in familial SVAS). Most cases of non-syndromic autosomal dominant SVAS are not associated with large DNA rearrangements.
In this study, we cloned human ELN, refined its genomic structure and used this information to develop oligonucleotide primers suitable for mutational analysis. Single strand conformation polymorphism analysis (SSCP) identified ELN point mutations in four familial and three sporadic cases of SVAS. Two of the mutations were nonsense, one was a frameshift and four were splice site mutations. In one sporadic case, the mutation arose de novo. These data establish that point mutations in ELN can cause autosomal dominant SVAS.
RESULTS

Genomic structure of ELN
Previous work on the genomic structure of human ELN did not define intron-exon boundaries or intronic sequences (12, 13) . To facilitate identification of point mutations in human ELN, we constructed a contiguous physical map comprised of cosmid and phage clones that span 55 kb of chromosome 7q11.23 ( Fig. 1) . The numbering of 34 exons in human ELN was based on homology with bovine ELN, which has 36 exons (12, 13) . Exons 34 and 35 of bovine ELN have no counterparts in human ELN.
The intron-exon boundaries are shown in Table 1 and are available in GenBank. Analysis of this structure indicated that the last nucleotide of each ELN exon is spliced with the first two nucleotides of the following exon to form a codon. Thus, removal of any internal ELN exon would not result in a frameshift but in the loss of amino acids encoded by the spliced exon. We designed oligonucleotide primers for mutational analyses from intronic sequences ( Table 2) . 
Numbering of the 34 exons in human ELN is based on homology with the bovine elastin gene, which has 36 exons. Exons 34 and 35 of bovine elastin have no counterparts in human ELN. DNA sequence for intron-exon boundaries are shown using the consensus sequence defined by Shapiro and Senapathy (32) . Intron sequences are shown in lower case, exon sequences in uppercase. The corresponding amino acids are listed below the exon sequences. The last nucleotide of each exon forms a codon with the first two nucleotides of the following exon. Exon 26 of human ELN has two alternative donor splice sites, resulting in an exon of either 126 or 225 bp. The donor site for the 126 bp product is listed as exon 26a while the donor site for the 225 product is listed as exon 26b.
SSCP analyses reveal ELN point mutations
To determine if ELN point mutations cause SVAS, we performed SSCP analyses on DNA samples of 20 unrelated individuals with familial and sporadic SVAS. No ELN rearrangements were identified in these DNA samples by fluorescence in situ hybridization, pulsed-field gel electrophoresis or Southern analyses (data not shown). Previous work demonstrated that SVAS was linked to a polymorphic marker near ELN in kindred 1779 (K1779; 5). SSCP analyses using primers amplifying exon 26 identified an anomalous band that co-segregated with the disease in this family (Fig.  2) . The aberrant conformer was not observed in DNA samples of >375 unaffected and unrelated control individuals. The conformer was cloned and sequenced, leading to the identification of a single nucleotide deletion at position 1821 in exon 26, 1821delC. This deletion caused a frameshift, resulting in a premature stop codon in exon 28. A second change, 1824C→T, identified in the aberrant conformer is silent.
Mutational analyses using primers for exons 21 and 25 defined aberrant conformers in two sporadic cases of SVAS, K2178 (Fig.  3A) and K2016 (Fig. 3B) . These anomalies were not seen in >375 control DNA samples. In K2178, a C to T transition was identified at nucleotide 1324, 1324C→T, resulting in a nonsense mutation in exon 21. In K2016, a C to T transition was identified at nucleotide 1708, 1708C→T, resulting in a nonsense mutation in exon 25. DNA samples could not be obtained from the parents of either proband.
SSCP analyses using primers for exon 16 demonstrated an identical anomalous conformer that co-segregated with the disease in two unrelated kindreds, K2260 and K2205 (Fig. 4) . Analyses of a third kindred, K2044, revealed a second anomalous band. These conformers were not seen in >375 control DNA samples. DNA sequence analyses revealed an A to G transition, IVS15-2A→G, (K2260 and K2205) and a C to G transversion, IVS15-3C→G, (K2044) in the splice acceptor site preceding exon 16.
Mutational analyses using primers flanking exon 3 revealed an anomalous conformer in a sporadic case of SVAS (K2017; Fig.  5 ). This conformer was not observed in the proband's parents, indicating that it arose de novo. Paternity and maternity were confirmed by genotypic analysis using seven short tandem repeat polymorphisms (data not shown). The anomaly was not observed in analyses of >375 control DNA samples. DNA sequence analyses revealed a G to A transition in the 5′ splice donor site following exon 3, IVS3+1G→A.
To determine if the point mutations described here result in the synthesis of abnormal or reduced mRNA ELN transcript, we used reverse transcriptase-polymerase chain reaction (RT-PCR) to isolate ELN transcripts from lymphoblastoid cells. However, we were unable to detect ELN transcripts from experimental and control lymphoblastoid cells. Skin fibroblasts were not available for study.
To determine if a specific ELN mutation could be used to predict the severity of vascular disease, we re-examined the phenotypic data in this genotypically defined population. We found that intrafamilial variability of phenotypic expression was as great as interfamilial variability. For example in K1779, the severity of the phenotype ranged from an asymptomatic 65-yearold male who had mild SVAS by echocardiography to a severely affected 16-year-old female who required surgical correction. In K2205, phenotypic variation ranged from an asymptomatic 50-year-old female who had minimal SVAS by cardiac angiography to a 4-year-old male with severe disease requiring surgical palliation. Of the 17 individuals with ELN point mutations, 16 have documented SVAS by echocardiography and/or angiography. For one individual with an ELN point mutation, the mother of the affected individual in K2260, we could not obtain phenotypic data. Thus, the penetrance in this study was 100%.
DISCUSSION
We conclude that point mutations in ELN cause an inherited vascular disorder, SVAS. In this study, we cloned human ELN, refined its genomic structure and used this information to synthesize oligonucleotide primers for mutational analyses. Using SSCP analyses, we identified ELN point mutations associated with disease in four SVAS families and three sporadic cases. These mutations included nonsense, frameshift and splice site mutations. In one case, we demonstrated that the ELN mutation arises de novo. Combined with existing molecular and histologic data, these findings establish that point mutations in ELN cause SVAS. All primers are shown 5′ to 3′. The size of the amplified product is listed on the right. Exon 18 has two sets of primers. Because of repetitive sequences near the splice donor site following exon 18, two 3′ or reverse primers were needed to amplify exon 18. The product from the first set of primers (18 forward and 18 reverse) is used as template in a second PCR reaction using 18 forward and 18B reverse.
The molecular consequences of the ELN point mutations described here are not yet known. It is of note that no missense mutations were identified in this study. The mutations defined here may lead to the synthesis of aberrant transcripts or may result in functional hemizygosity. Hemizygosity of ELN is established as the mechanism of SVAS in Williams syndrome (11) . If mutant transcripts are stable, some would result in the production of elastin protein lacking the carboxy-terminus (Fig. 6) . The carboxyl end of elastin contains two cysteine residues that are thought to be critical for interaction with microfibrillar-associated glycoprotein during elastogenesis (14, 15) . The loss of the carboxyl end of elastin protein could result in aberrant elastic fiber formation during vasculogenesis (16) .
We identified three splice site mutations in individuals with SVAS. These mutations affected exons 3 and 16. Previous studies have demonstrated that mutations in the consensus sequence of either the splice acceptor site preceding an exon, or a splice donor site following an exon, can result in removal of that exon from the mature transcript (17, 18) . If no cryptic splice sites are present, the splice mutations of exons 3 and 16 would delete these exons (Fig.  6) . Because of ELN's genomic organization, deletion of an exon results in the loss of the amino acids encoded by the exon, not in a frameshift. Exon 3 encodes a hydrophobic domain that may be important for the tertiary structure of elastin. Exon 16 encodes a relatively large hydrophobic domain that separates two alaninerich cross-linking sites near the center of the molecule. Deletion of exon 16 would result in the juxtaposition of two cross-linking domains and may have a deleterious effect on the spatial symmetry required to form a functional interaction between cross-linking sites. In addition, exon 16 contains a hexapeptide sequence (PGAIPG) that interacts with elastin-binding proteins on the surface of cells (19, 20) . Thus, deletion of exon 16 could disrupt both the structural integrity and the cellular interaction of elastin.
We performed mutational analysis in 20 unrelated cases of SVAS and discovered mutations in seven. This relative insensitivity could be due to the technique (SSCP), but the gels were run under two conditions to increase sensitivity. In addition, we did not examine the 5′-or 3′-untranslated region of ELN. Finally, it is possible that SVAS is genetically heterogeneous. These issues must be addressed if genetic testing for SVAS is to become routine.
In this study, we found that intrafamilial variability of phenotypic expression in SVAS is high, a finding consistent with previous studies (9, 10, 21, 22) . In one study, Olson and co-workers described a family with an intragenic deletion of ELN. In a second report, Curran et al. characterized an SVAS family harboring a balanced translocation that disrupted the 3′ end of ELN. Phenotypes in both families ranged from severe generalized obstructive disease requiring surgery at an early age to modest asymptomatic focal vascular abnormalities documented late in life through clinical testing. This phenotypic variability will limit the prognostic utility of genetic testing. Epidemiological and biochemical studies have led to the hypothesis that the pathogenesis of obstructive vascular disease is complex, resulting from the interplay of multiple heritable and environmental factors. Several major risk factors for vascular disease have been identified, including hypercholesterolemia, hypertension and diabetes, but these factors are thought to account for only 50% of heritable risk (23) (24) (25) . The abundance of elastin in the vasculature, the importance of elasticity to the Human Molecular Genetics, 1997 , Vol. 6, No. 7 1027 modulation of hemodynamic stress, and our demonstration that ELN mutations cause SVAS suggest that elastin abnormalities could contribute to common vascular disease. The synthesis of oligonucleotide primers useful for mutational analyses will enable future studies on the role of ELN as a genetic risk factor for common vascular disease.
MATERIALS AND METHODS
Phenotypic evaluation
Informed consent was obtained from all study participants in accordance with standards established by local institutional review boards. To determine if family members and spouses had SVAS or Williams syndrome, physical examinations and echocardiograms were performed by a medical geneticist and a cardiologist, as previously described (26) . In this study, individuals with an unknown phenotype were given that designation due to our inability to obtain an echocardiogram.
DNA sequence and exon-intron determination
Genomic clones were isolated from phage and cosmid libraries by probing with ELN cDNA. Four clones contained elastin exons (λ-4, λ-5, cELN-11d and cELN-6). These clones were mapped by restriction analyses and spanned exons 1-36 of ELN (Fig. 1) .
Phage clones λ-4 and λ-5 and cosmid clones cELN-6 and cELN-11d were subcloned into pBluescript II SK+ from Stratagene (La Jolla). Subclones were sequenced in both orientations with dye-labeled primers (M13-21 and M13RP) on an ABI 373 automated sequencer. Sequenced fragments were assembled using the genome assembly program (27, 28) . Continuous coverage of this region was obtained by generation of nested deletions using Deletion Factory System Version 2.0 from Gibco-BRL (Gaithersberg, MD).
The complete sequence spanning exon 5 to 10 kb 3′ of exon 36, and 70% of the region between exons 2 and 5 were sequenced. The intron-exon boundaries for exons 2-36 were defined. The intron-exon boundary for exon 1 was described previously (12) . Restriction maps predicted by the sequence data were identical to maps generated with EcoRI, HindIII and BamHI. These data were submitted to GenBank (Accession nos U93034, U93035, U93036 and U93037).
SSCP analysis
Oligonucleotide primers amplifying each exon of ELN were designed and used for mutational analyses. Genomic DNA samples were amplified by PCR and used in SSCP analyses as described (29, 30) . The annealing temperature was 58_C for all PCR reactions. Reactions (10 µl) were diluted with 40 µl of 0.1% SDS/1 mM EDTA and 30 µl of 95% formamide dye. Diluted products were denatured by heating at 100_C for 5 min, and 3 µl of each sample was electrophoresed on 7.5% non-denaturing acrylamide gels (49:1 polyacrylamide:bis-acrylamide) at 4_C. Electrophoresis was carried out at 40 W for 2-5 h. Gels were dried and exposed to X-ray film at -80_C for 12-36 h.
Normal and aberrant SSCP conformers were cut directly from dried gels and eluted in 75 µl of distilled water at 37_C for 30 min. Ten µl of the eluted DNA was used as template for a second PCR reaction using the original primer pair. Products were fractionated in 2% low melting temperature agarose gels, and bands cloned directly into pBluescript II SK+ using the T-vector method as described (31) . Plasmid DNA samples were purified and sequenced.
